title: Global Aesthetics Consensus: Avoidance and Management of Complications from Hyaluronic Acid Fillers-Evidence- and Opinion-Based Review and Consensus Recommendations.
abstract: BACKGROUND
  Although the safety profile of hyaluronic acid fillers is favorable, adverse reactions can occur. Clinicians and patients can benefit from ongoing guidance on adverse reactions to hyaluronic acid fillers and their management.
  
  
  METHODS
  A multinational, multidisciplinary group of experts in cosmetic medicine convened the Global Aesthetics Consensus Group to review the properties and clinical uses of Hylacross and Vycross hyaluronic acid products and develop updated consensus recommendations for early and late complications associated with hyaluronic acid fillers.
  
  
  RESULTS
  The consensus panel provided specific recommendations focusing on early and late complications of hyaluronic acid fillers and their management. The impact of patient-, product-, and technique-related factors on such reactions was described. Most of these were noted to be mild and transient. Serious adverse events are rare. Early adverse reactions to hyaluronic acid fillers include vascular infarction and compromise; inflammatory reactions; injection-related events; and inappropriate placement of filler material. Among late reactions are nodules, granulomas, and skin discoloration. Most adverse events can be avoided with proper planning and technique. Detailed understanding of facial anatomy, proper patient and product selection, and appropriate technique can further reduce the risks. Should adverse reactions occur, the clinician must be prepared and have tools available for effective treatment.
  
  
  CONCLUSIONS
  Adverse reactions with hyaluronic acid fillers are uncommon. Clinicians should take steps to further reduce the risk and be prepared to treat any complications that arise.
authors.affiliation: Milan, Italy; Sydney, New South Wales, and Carlton, Victoria, Australia; Rockville, Md.; Aalst, Belgium; Birmingham, Ala.; Beijing, People's Republic of China; São Paolo and Rio de Janeiro, Brazil; and Montreal, Quebec, Canada.
authors.forename: Massimo
authors.initials: M
authors.lastname: Signorini
authors.forename: Steven
authors.initials: S
authors.lastname: Liew
authors.forename: Hema
authors.initials: H
authors.lastname: Sundaram
authors.forename: Koenraad L
authors.initials: KL
authors.lastname: De Boulle
authors.forename: Greg J
authors.initials: GJ
authors.lastname: Goodman
authors.forename: Gary
authors.initials: G
authors.lastname: Monheit
authors.forename: Yan
authors.initials: Y
authors.lastname: Wu
authors.forename: Ada R
authors.initials: AR
authors.lastname: Trindade de Almeida
authors.forename: Arthur
authors.initials: A
authors.lastname: Swift
authors.forename: André
authors.initials: A
authors.lastname: Vieira Braz
mesh_terms: D000465:Algorithms; D001291:Attitude of Health Personnel; D002983:Clinical Competence; D032921:Consensus; D004954:Esthetics; D019317:Evidence-Based Medicine; D006301:Health Services Needs and Demand; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage* / Q000009:adverse effects*; D011183:Postoperative Complications / Q000209:etiology* / Q000517:prevention & control* / Q000628:therapy; D012307:Risk Factors; D013518:Surgery, Plastic
chemical_list: D006820:Hyaluronic Acid